close

Fundraisings and IPOs

Date: 2016-12-16

Type of information: Private placement

Company: Soligenix (USA - NJ)

Investors:

Amount: $ 5.28 million

Funding type: private placement

Planned used:

Others: * On December 16, 2016, Soligenix announced the closing of its previously announced underwritten public offering of 1,670,000 shares of its common stock and warrants to purchase up to an aggregate of 2,087,500 shares of its common stock at a combined offering price of $3.16. In addition, the underwriters partially exercised the over-allotment to purchase an additional 282,505 warrants. The warrants have a per share exercise price of $3.95, are exercisable immediately and will expire five years from the date of issuance. Gross proceeds to Soligenix, Inc. from this offering are approximately $5,277,270 before deducting underwriting discounts and commissions and other estimated offering expenses payable by Soligenix. * On December 13, 2016, Soligenix announced the pricing of an underwritten public offering of 1,670,000 shares of its common stock and warrants to purchase up to an aggregate of 2,087,500 shares of its common stock at a combined offering price of $3.16. The warrants will have an initial per share exercise price of $3.95, subject to customary adjustment in connection with stock splits, stock dividends, reclassifications, combinations and other similar events, are exercisable immediately and will expire five years from the date of issuance. The gross proceeds to Soligenix, Inc. from this offering are expected to be approximately $5,277,200, before deducting underwriting discounts and commissions and other estimated offering expenses. Soligenix, Inc. has granted the underwriters a 45-day option to purchase up to an additional 250,500 shares of common stock and/or 313,125 additional warrants to cover over-allotments, if any. The offering is expected to close on December 16, 2016, subject to customary closing conditions. Aegis Capital Corp. is acting as the sole book-running manager for the offering. Maxim Group LLC is acting as co-manager for the offering.

Therapeutic area: Rare diseases

Is general: Yes